NanoViricides Says Clinical Trial Of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Satisfactorily
NanoViricides Says Clinical Trial Of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Satisfactorily
NanoViricides表示，其廣譜抗病毒藥物nv-CoV-2的臨床試驗進展令人滿意
Following safety and tolerability evaluation in healthy persons for a single escalating dose of NV-CoV-2 Oral Syrup or NV-CoV-2 Oral Gummies in the Part 1a, the clinical trial will continue into Part 1b if there are no serious adverse events.
在健康人對第1a部分中單次遞增劑量的nv-CoV-2口服糖漿或nv-CoV-2口服軟糖進行安全性和耐受性評估後，如果沒有嚴重的不良事件，臨床試驗將持續到第1b部分。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。